Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pixantrone with rituximab, ifosfamide, and etoposide in relapsed or refractory CD20-positive aggressive non-Hodgkin lymphoma
2017-000719-17Phase 2Completed
- Sponsor
- LYSARC
- Start
- Dec 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pixantrone in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by LYSARC. Primary endpoint: Overall Metabolic Response rate. Started Dec 2017; status: completed.
02
Drugs
pixantrone
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on 2017-000719-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000719-17.